Skip to main content
. 2022 Dec 3;21:267. doi: 10.1186/s12933-022-01709-z

Fig. 1.

Fig. 1

Timeline of the study design. Subjects without diabetes were followed from the first examination to the second examination for the fasting plasma glucose (FPG) changes [1] Normal fasting glucose (NFG) to NFG, [2] NFG to impaired fasting glucose (IFG), [3] NFG to type 2 diabetes mellitus (T2DM), [4] IFG to NFG, [5] IFG to IFG [6] IFG to T2DM. *Only ARIC and TLGS participants were assessed for cancer mortality outcomes and followed-up for a median of 25.1 years